| No. |
Proposition |
|
For |
Against |
Abstain |
| 1 |
Approval of the parent company financial statements for the financial year ended December 31, 2025 |
|
|
|
|
| 2 |
Approval of the consolidated financial statements for the financial year ended December 31, 2025 |
|
|
|
|
| 3 |
Allocation of loss for the financial year ended December 31, 2025 |
|
|
|
|
| 4 |
Approval of the regulated agreements entered into between certain subsidiaries of the Company and companies of the Sanofi Group |
|
|
|
|
| 5 |
Renewal of Mr. Emmanuel Blin’s term of office as director |
|
|
|
|
| 6 |
Renewal of Ms. Elizabeth Bastoni’s term of office as director |
|
|
|
|
| 7 |
Renewal of Ms. Ccile Dussart’s term of office as director |
|
|
|
|
| 8 |
Renewal of Sanofi Aventis Participations’s term of office as director |
|
|
|
|
| 9 |
Renewal of Bpifrance Investissement’s term of office as director |
|
|
|
|
| 10 |
Renewal of Ms. Graldine Leveau’s term of office as director |
|
|
|
|
| 11 |
Renewal of Mr. Mattias Perjos’s term of office as director |
|
|
|
|
| 12 |
Ratification of the co-optation of Mr. Tristan Imbert as director |
|
|
|
|
| 13 |
Renewal of Mr. Tristan Imbert’s term of office as director |
|
|
|
|
| 14 |
Approval of the information referred to in article L. 22-10-9, paragraph I of the French Commercial Code relating to remuneration paid during or awarded in respect of the financial year ended December 31, 2025 to corporate officers |
|
|
|
|
| 15 |
Approval of the fixed, variable and exceptional components of the total remuneration and benefits of any kind paid during the financial year ended December 31, 2025 or awarded in respect of the same financial year to Mr. Emmanuel Blin, in respect of his office as Chair of the board of directors of the Company |
|
|
|
|
| 16 |
Approval of the fixed, variable and exceptional components of the total remuneration and benefits of any kind paid during the financial year ended December 31, 2025 or awarded in respect of the same financial year to Mr. David Seignolle, in respect of his office as Chief Executive Officer of the Company |
|
|
|
|
| 17 |
Approval of the variable components of the remaining balance of remuneration paid during the financial year ended December 31, 2025 to Mr. Ludwig de Mot, in respect of his office as Chief Executive Officer of the Company from March 1, 2024 to December 9, 2024 |
|
|
|
|
| 18 |
Approval of the remuneration policy for members of the board of directors |
|
|
|
|
| 19 |
Approval of the remuneration policy for Mr. Emmanuel Blin, Chair of the board of directors |
|
|
|
|
| 20 |
Approval of the remuneration policy for Mr. David Seignolle, Chief Executive Officer of the Company |
|
|
|
|
| 21 |
Ratification of the transfer of the registered office (ratification of the decision of the board of directors to transfer the Company’s registered office and to amend to Article 4 (“Registered Office”) of the articles of association |
|
|
|
|
| 22 |
Authorization to be granted to the Board of Directors to purchase, hold or transfer shares in the Company |
|
|
|
|
| 23 |
Authorization for the board of directors to reduce the share capital by cancelling shares under the authorization to repurchase the Company's own shares |
|
|
|
|
| 24 |
Authorization to be granted to the board of directors to grant free shares, existing or to be issued, which results in the waiver by the shareholders of their preferential subscription rights |
|
|
|
|
| 25 |
Powers for formalities. |
|
|
|
|